ClinicalTrials.gg
RecruitingNCT05794022HIBISCUS STEMIUpdated May 14, 2026

Cohort of STEMI Patients 2

An interventional study of MRI and Biocollection in Myocardial Infarction, sponsored by Hospices Civils de Lyon. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Primary conditionST Elevation Myocardial InfarctionRegistry: Myocardial InfarctionReclassifiedWhy we changed it
Registry
Myocardial Infarction — the first condition term the registry derived for this study.
ClinicalTrials.gg
ST Elevation Myocardial Infarction
Why
  1. The study's title name ST Elevation Myocardial Infarction, a narrower term within Myocardial Infarction.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in ST Elevation Myocardial Infarction with a site in France — 7 open to participants now, 11 under way, 5 of them phase 3. ST Elevation Myocardial Infarction · France.

Planned enrollment
25th of 40
300 · median 325
Started
2023
with 3 others
No phase
17 of 49
2 open now
Primary completion
2033-06
later than 10 of 10 live
Registered
43rd of 49
by date
Lead sponsor
6 of 49
Hospices Civils de Lyon

Among the 49 studies in ST Elevation Myocardial Infarction with a site in France, this one is the 25th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 43rd registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

7 of the 49 studies in ST Elevation Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in ST Elevation Myocardial Infarction with a site in France, or all of them as a file.
02

Study summary

ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort).

The purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.

03

Conditions studied

  • Myocardial Infarction

Browse trials for

Keywords

  • Myocardial infarction
  • bio-collection
  • Imaging markers
  • biomarkers
  • STEMI
  • clinical outcomes
04

In context

ST Elevation Myocardial Infarction Reclassified

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

This study's planned enrollment of 300 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Compared within ST Elevation Myocardial Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead .
  • Management in primary ACT
  • Prior oral followed by signed informed consent as soon as possible.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of STEMI not confirmed on angiography
  • Inability to give the subject informed information
  • Lack of coverage by a social security scheme
  • Obvious to injected magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal insufficiency (\<30 ml/min), known allergy to the contrast medium ....)
  • Pregnant woman or woman of childbearing age without effective , breastfeeding woman.
  • Deprivation of civil rights (curators, guardianship, safeguard of justice)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Cohort group

    patient with ST-segment elevation myocardial infarction.

    Other: MRI · Biological: Biocollection · Behavioral: Quality of life questionaries

Interventions

  • OtherMRI

    1 MRI at 1 month with gadolinium injection

  • BiologicalBiocollection

    Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.

  • BehavioralQuality of life questionaries

    EQ-5D-5L and HAD questionaries at 1 month and 1 year.

07

What researchers measure

Primary outcomes

  1. Research of potential new markers

    Biomarkers assays (prognosis and diagnosis) between inclusion and one-year follow-up (H0, H4, H24, H48, M1, M12 since emergency revascularisation)

    Time frame: 1 year

Secondary outcomes

  1. Calculation of infarct size on MRI

    Measurement of reperfusion lesions on MRI (mass in grams)

    Time frame: 1 month

  2. Pharmacoepidemiology of myocardial infarction.

    Description and evolution of patients' medical treatment between hospital discharge and 5 years follow-up.

    Time frame: 5 years

  3. Events between inclusion and 5 years follow-up

    Time to a major adverse cardiovascular event

    Time frame: 5 years

08

Study locations

2 of 2 sites recruiting
09

References and documents

Publications

  • Stevic N, Pinede A, Mewton N, Ovize M, Argaud L, Lecour S, Boiteux C, Bochaton T, Cour M. Effect of ventricular fibrillation on infarct size after myocardial infarction: a translational study. Basic Res Cardiol. 2024 Dec;119(6):911-921. doi: 10.1007/s00395-024-01091-9. Epub 2024 Nov 23. PubMed 39579225 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jun 2033, 121 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 121 months is above that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
Mar 31, 2023
StartActual
May 3, 2023
Primary completionEst.
Jun 3, 2033
CompletionEst.
Jun 3, 2033
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05794022
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
May 3, 2023
Primary completion
Jun 3, 2033 (estimated)
Completion
Jun 3, 2033 (estimated)
Last update
May 14, 2026

Study contacts

Thomas BOCHATON, Dr
Contact
thomas.bochaton@chu-lyon.fr
04 72 35 75 41 ext. +33
Yvonne VARILLON
Contact
yvonne.varillon@chu-lyon.fr
04 72 35 69 64 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion